Efficacy of Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitors in Renal Anemia: Enhancing Erythropoiesis and Long-Term Outcomes in Patients with Chronic Kidney Disease
HIF-PHIs can serve as an alternative to ESA for managing renal anemia in CKD, improving both hematological parameters and long-term outcomes.
Authors
- Tomoaki Takata (ORCID: https://orcid.org/0000-0003-2959-6015)
- Yukari Mae (ORCID: https://orcid.org/0000-0002-8293-1620)
- Ken Kageyama (ORCID: https://orcid.org/0000-0002-0787-9789)
- Takuji Iyama
- Katsuya Hikita (ORCID: https://orcid.org/0000-0002-2156-6084)
- Yoko Yoshida (ORCID: https://orcid.org/0000-0001-6624-6976)
- Hajime Isomoto (ORCID: https://orcid.org/0000-0001-8858-6525)
- Hinako Hanada
- Yudai Fujino
- Sosuke Taniguchi
Institutions
- Tottori University Hospital (JP)
- Tottori University (JP)
Publication Details
- Journal
- Biomedicines
- Published
- 2024-12-23
- DOI
- https://doi.org/10.3390/biomedicines12122926
- Primary Topic
- Erythropoietin and Anemia Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00